Table 6.
B-Cell and T-Cell Counts at First RTX/OCR Infusion and after 6 Months by Patient Group
| “No therapy” | “Short-FING” | “Long-FING” | “Low efficacy therapy” | “NTZ” | |
| B-cell count at the first RTX/OCR infusion | 283 (149)a | 106 (88)a,b,c | 145 (83)a,b,c | 335 (170) | 583 (314) |
| T-cell count at the first RTX/OCR infusion | 1,688 (640) | 754 (494)a,b,c | 913 (429)a,b,c | 1,458 (706) | 2,142 (1,006) |
| CD4+ T-cell count at the first RTX/OCR infusion | 1,074 (502) | 399 (322)a,b,c | 550 (309)a,b | 884 (499) | 1,309 (652) |
| CD8+ T-cell count at the first RTX/OCR infusion | 544 (167) | 325 (208)a,b | 328 (157)a,b | 451 (313)a | 767 (406) |
| B-cell count 6 mo after RTX/OCR infusion | 21 (48) | 15 (30) | 13 (28) | 15 (27) | 17 (34) |
| T-cell count 6 mo after RTX/OCR infusion | 1,655 (591) | 994 (457)a,b | 1,066 (449)a,b | 1,319 (474) | 1,381 (544) |
| CD4+ T-cell count 6 mo after RTX/OCR infusion | 1,048 (419) | 600 (317)a,b | 632 (275)a,b | 793 (324) | 863 (383) |
| CD8+ T-cell count 6 mo after RTX/OCR infusion | 507 (207) | 334 (141)a,b | 397 (272)b | 440 (206) | 470 (221) |
Data are mean (SD).
RTX, rituximab; OCR, ocrelizumab; “no therapy”: no disease-modifying therapy before RTX/OCR; “low efficacy therapy”: beta-interferon formulations, glatiramer acetate, or dimethyl fumarate before RTX/OCR; “NTZ”: natalizumab before RTX/OCR; “short-FING”: previously received fingolimod with a washout period less than the median value of the washout period duration of the “FING” group (27 d); “long-FING”: previously received fingolimod with a washout period greater than or equal to the median value of the washout period duration of the “FING” group (27 d).
Lower cell count than “NTZ,” p < 0.05.
Lower cell count than “no therapy,” p < 0.05.
Lower cell count than “BASIC,” p < 0.05.